News

UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.
Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.
Jasper Therapeutics’ stock has dropped after it announced it was investigating the impact of a faulty batch of its investigational antibody therapy dosed in a Phase Ib/IIa trial.
PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.
PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.
Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).
Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.
The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...
Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.
Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.
Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...
INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.